New York, October 21, 2016 -- Moody's Investors Service commented that the positive clinical data of Alkermes' experimental depression drug ALKS-5461 is credit positive. There is no effect on Alkermes' ratings including the Ba3 Corporate Family Rating, or the negative rating outlook.

Vollständigen Artikel bei Moodys lesen